Description
VDBEST-D 10/100 Tablet is described as a combination of Vildagliptin 100 mg + Dapagliflozin 10 mg, intended for type 2 diabetes management. Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. These medicine classes support blood glucose regulation through different mechanisms.
Vildagliptin helps regulate glucose-dependent insulin and glucagon responses, while dapagliflozin reduces glucose reabsorption in the kidneys, allowing more glucose to be excreted in urine. The suitability of this combination depends on the patient’s medical condition, kidney function, other medicines and the approved product information.
CardianCare is associated with cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Vildagliptin 100 mg + Dapagliflozin 10 mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing details and applicable quality documentation.
For procurement teams evaluating a Vildagliptin 100 mg + Dapagliflozin 10 mg Tablets manufacturer and supplier India, important checks include the exact composition, release characteristics, regulatory authorisation, packaging, batch traceability, shelf life and applicable commercial terms.
Important composition check: Vildagliptin is commonly marketed in immediate-release strengths, and a 100 mg sustained-release formulation requires confirmation against the approved product label. Verify the stated strength, release type and regulatory status before publishing or promoting this product.
2. Key Ingredient
Composition provided:
Vildagliptin 100 mg + Dapagliflozin 10 mg
Vildagliptin: Vildagliptin is a DPP-4 inhibitor. It helps prolong the activity of incretin hormones, supporting glucose-dependent insulin secretion and helping regulate glucagon secretion when blood glucose levels are elevated. The exact strength and sustained-release formulation must be verified against approved product information.
Dapagliflozin: Dapagliflozin is an SGLT2 inhibitor. It reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion and helping lower blood glucose levels. Depending on the approved indication and patient profile, dapagliflozin may also have specific heart failure or kidney-related indications; these must not be assumed for every product or patient.
Businesses researching a Vildagliptin 100 mg + Dapagliflozin 10 mg pharmaceutical company India should review the composition, approved release formulation, product authorisation and quality assurance documentation.
Companies seeking a Vildagliptin 100 mg + Dapagliflozin 10 mg medicine manufacturer India should verify the authorised manufacturing facility, product registration, applicable regulatory requirements and batch-specific quality records before procurement.
3. Key Benefits
Blood glucose management: The individual ingredients act through different pathways that may support type 2 diabetes management when an approved combination is clinically appropriate.
Complementary mechanisms: DPP-4 inhibition and SGLT2 inhibition target different processes involved in blood glucose regulation.
Incretin-related activity: Vildagliptin supports glucose-dependent insulin and glucagon regulation, subject to confirmation of the stated formulation.
Renal glucose excretion: Dapagliflozin helps increase the amount of glucose removed through urine.
Treatment planning: Combination therapy may be considered by a clinician when the individual medicines and doses are appropriate for the patient.
Comprehensive diabetes care: Medicines work best as part of an individualised plan that includes dietary measures, physical activity and medical monitoring.
Benefits and suitability vary between patients. Do not assume that the proposed combination or its stated sustained-release formulation is approved until the product’s regulatory status has been verified.
Pharmaceutical buyers searching for a Vildagliptin 100 mg + Dapagliflozin 10 mg supplier India should confirm product availability, authenticity, approved packaging, storage conditions and shelf life.
A Vildagliptin 100 mg + Dapagliflozin 10 mg Tablet wholesaler and distributor India enquiry may include stock availability, minimum order quantities, distribution eligibility, delivery coverage and applicable commercial terms.
Businesses seeking a Vildagliptin 100 mg + Dapagliflozin 10 mg bulk supplier India should request a formal quotation and confirm batch traceability, packaging specifications and quality documentation.
A Vildagliptin 100 mg + Dapagliflozin 10 mg pharmaceutical distributor India should verify the product’s authorisation, applicable licensing requirements and approved promotional information before commercial distribution.
4. How Does It Work?
Vildagliptin: Vildagliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones such as GLP-1 and GIP. By prolonging their activity, it supports glucose-dependent insulin secretion and helps regulate glucagon secretion.
Dapagliflozin: Dapagliflozin inhibits the SGLT2 protein in the kidneys, reducing glucose reabsorption into the bloodstream. As a result, more glucose is eliminated through urine.
These mechanisms are different and may provide complementary glucose-lowering effects when the medicines are prescribed appropriately. However, the exact proposed combination and sustained-release formulation require confirmation before product-specific claims are made.
5. Directions for Use
Dosage: Use only as prescribed by a qualified doctor after the exact product composition and approved formulation have been confirmed.
Administration: Follow the approved product label and the prescriber’s instructions. Do not crush, split or alter a sustained-release Tablet unless the product information specifically permits it.
Regular timing: Follow the prescribed schedule consistently. Do not change the dose independently.
Kidney function: Kidney function should be assessed before and during treatment as clinically indicated. Dapagliflozin’s suitability and glucose-lowering effect can depend on renal function.
Hydration: Dapagliflozin can increase urinary fluid loss. Follow medical advice about hydration, particularly during hot weather, illness or fluid restriction.
Missed dose: Follow the approved patient information leaflet or ask a doctor or pharmacist for advice. Do not double the next dose.
Monitoring: Follow recommended blood glucose monitoring and medical appointments.
Illness and procedures: Inform the healthcare professional about planned surgery, prolonged fasting or serious illness because SGLT2 inhibitors may require temporary interruption under medical guidance.
Do not use this information to determine a dose. The exact composition, release characteristics and approved prescribing information must be verified first.
6. Possible Side Effects
Potential side effects associated with the individual medicine classes may include:
Increased urination
Genital fungal infections
Urinary tract symptoms or infections
Dizziness
Dehydration or low blood pressure
Gastrointestinal discomfort
Important adverse reactions requiring medical attention:
Diabetic ketoacidosis: SGLT2 inhibitors such as dapagliflozin have been associated with ketoacidosis, sometimes even when blood glucose is not markedly elevated. Symptoms can include nausea, vomiting, abdominal pain, unusual fatigue or difficulty breathing. Seek urgent medical care.
Volume depletion: Dizziness, fainting or signs of dehydration require medical assessment.
Hypoglycaemia: Risk may increase when used with insulin or sulfonylureas.
Genital or urinary infections: Pain, fever, unusual discharge or persistent symptoms should be assessed by a healthcare professional.
Pancreatitis: Severe, persistent abdominal pain requires urgent medical evaluation.
Allergic reactions: Swelling of the face or throat, breathing difficulty or a severe rash requires emergency care.
This is not a complete list. Consult approved prescribing information for each active ingredient and seek professional advice about persistent or concerning symptoms.
7. Safety Information
Product verification: Confirm that the stated Vildagliptin 100 mg sustained-release strength and formulation are approved and match the actual product label before use or promotion.
Medical supervision: Use only when prescribed by a qualified healthcare professional.
Kidney health: Assess kidney function and the suitability of dapagliflozin according to the approved indication and prescribing information.
Liver health: Vildagliptin may require liver function assessment and monitoring according to approved product information.
Ketoacidosis risk: Inform the doctor about previous ketoacidosis, prolonged fasting, surgery, acute illness or markedly reduced food intake.
Fluid balance: Discuss dehydration, low blood pressure, diuretic use and other conditions that may increase fluid loss.
Pregnancy and breastfeeding: Seek medical advice before use during pregnancy, when planning pregnancy or while breastfeeding. SGLT2 inhibitors are generally not recommended during the later stages of pregnancy, and alternative treatment may be required.
Drug interactions: Tell the doctor about all prescription medicines, over-the-counter products and supplements, especially insulin, sulfonylureas and diuretics.
Alcohol: Ask a healthcare professional about alcohol use, particularly if there are risks of dehydration or ketoacidosis.
Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of reach of children.
Professional review: Do not assume that the proposed combination is interchangeable with separately prescribed medicines or other formulations.
This information is educational and does not replace approved prescribing information or individual medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare is associated with cardiac and diabetic healthcare products and provides a point of contact for pharmaceutical trade enquiries. Healthcare professionals, pharmacists, wholesalers, distributors and eligible business partners should confirm current product availability and commercial arrangements directly with the company.
Businesses researching a Vildagliptin 100 mg + Dapagliflozin 10 mg PCD pharma franchise India opportunity can enquire about current product availability, partner eligibility, territory terms and applicable business requirements.
For a Vildagliptin 100 mg + Dapagliflozin 10 mg Tablets PCD pharma franchise enquiry, prospective partners can request details about product listings, minimum order requirements, distribution eligibility and any promotional support that may be available.
Companies exploring a Vildagliptin 100 mg + Dapagliflozin 10 mg Tablet PCD franchise should confirm that the exact formulation is authorised and included in any current programme before making commercial commitments.
Businesses evaluating Vildagliptin 100 mg + Dapagliflozin 10 mg third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Due diligence should include formulation feasibility, manufacturing permissions, applicable GMP compliance, product approvals and quality documentation.
A Vildagliptin 100 mg + Dapagliflozin 10 mg Tablet third party manufacturer India enquiry should cover the authorised manufacturing facility, release-formulation specifications, quality systems, batch release procedures and regulatory responsibilities.
Companies researching Vildagliptin 100 mg + Dapagliflozin 10 mg contract manufacturing India should verify service availability directly with the proposed manufacturing partner and review technical documentation, quality agreements, product authorisation and commercial feasibility.
Contact CardianCare through its official website to enquire about current product availability and eligible pharmaceutical business opportunities. Distribution, franchise and manufacturing arrangements must be confirmed directly with the company; do not advertise these services as available without verification.
For more information about VDBEST-D 10/100 Tablet (Vildagliptin 100 mg + Dapagliflozin 10 mg), click here













Reviews
There are no reviews yet.